JPMorgan Funds - Global Healthcare Fund I2 (acc) - EURRegister to Unlock Ratings |
Performance History | 31/10/2024 |
Growth of 1,000 (GBP) | Advanced Graph |
Fund | - | - | - | - | 5.8 | |
+/-Cat | - | - | - | - | 2.0 | |
+/-B’mrk | - | - | - | - | -1.6 | |
Category: Sector Equity Healthcare | ||||||
Category Benchmark: Morningstar Gbl Health TME ... |
Key Stats | ||
NAV 21/11/2024 | EUR 107.33 | |
Day Change | 0.28% | |
Morningstar Category™ | Sector Equity Healthcare | |
ISIN | LU2610165917 | |
Fund Size (Mil) 21/11/2024 | USD 3977.30 | |
Share Class Size (Mil) 21/11/2024 | EUR 19.08 | |
Max Initial Charge | - | |
Ongoing Charge 18/07/2024 | 0.76% |
Investment Objective: JPMorgan Funds - Global Healthcare Fund I2 (acc) - EUR |
To achieve a return by investing primarily in pharmaceutical, biotechnology, healthcare services, medical technology and life sciences companies ("Healthcare Companies"), globally. |
Returns | |||||||||||||
|
Management | ||
Manager Name Start Date | ||
Dominic Valder 05/10/2022 | ||
Bartjan van Hulten 28/02/2024 | ||
Inception Date 20/04/2023 |
Advertisement |
Category Benchmark | |
Fund Benchmark | Morningstar Benchmark |
MSCI World/Health Care NR USD | Morningstar Gbl Health TME NR USD |
Target Market | ||||||||||||||||||||
|
Portfolio Profile for JPMorgan Funds - Global Healthcare Fund I2 (acc) - EUR | 31/10/2024 |
|
|
Top 5 Holdings | Sector | % |
Eli Lilly and Co | Healthcare | 8.86 |
UnitedHealth Group Inc | Healthcare | 8.04 |
AbbVie Inc | Healthcare | 6.26 |
Novo Nordisk AS Class B | Healthcare | 5.78 |
Thermo Fisher Scientific Inc | Healthcare | 4.41 |
Increase Decrease New since last portfolio | ||
JPMorgan Funds - Global Healthcare Fund I2 (acc) - EUR |